Bristol Myers Squibb...announced that the U.S. Food and Drug Administration (FDA) approved CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more (Businesswire) - Sep 30, 2026 - "This FDA approval is based on positive results from the Phase 3 SCOUT-HCM trial, which evaluated the efficacy and safety of CAMZYOS (n=23) versus placebo (n=21) in patients aged 12 to <18 years with symptomatic NYHA (New York Heart Association) Class II-III obstructive hypertrophic cardiomyopathy."
FDA approval • Obstructive Hypertrophic Cardiomyopathy
|